Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SHE:301246)
25.89
+0.69 (2.74%)
At close: Apr 29, 2026
SHE:301246 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 472.74 | 745.59 | 421.86 | 395.19 | 120.43 |
Short-Term Investments | - | 379.25 | 292.31 | 90 | - |
Trading Asset Securities | 1,128 | 900.32 | 1,466 | - | - |
Cash & Short-Term Investments | 1,601 | 2,025 | 2,180 | 485.19 | 120.43 |
Cash Growth | -20.95% | -7.10% | 349.31% | 302.89% | -55.02% |
Accounts Receivable | 904.42 | 559.44 | 602.64 | 660.21 | 458.16 |
Other Receivables | 46.7 | 79.89 | 141.67 | 87.6 | 45.85 |
Receivables | 951.12 | 639.33 | 744.3 | 747.8 | 504.01 |
Inventory | 319.01 | 270.53 | 191.51 | 352.95 | 384.48 |
Other Current Assets | 425.86 | 111.34 | 86.43 | 78.98 | 20.72 |
Total Current Assets | 3,297 | 3,046 | 3,202 | 1,665 | 1,030 |
Property, Plant & Equipment | 2,364 | 2,292 | 1,910 | 1,620 | 891.27 |
Long-Term Investments | 211.24 | 203.64 | 228.08 | 335.12 | 242.35 |
Other Intangible Assets | 178.84 | 181.89 | 183.06 | 173.62 | 194.15 |
Long-Term Deferred Tax Assets | 19.66 | 17.26 | 17.56 | 21.22 | 17.72 |
Long-Term Deferred Charges | 4.08 | 5.52 | 5.95 | 6.86 | 11.98 |
Other Long-Term Assets | 89.59 | 78.06 | 103.9 | 53.27 | 45.14 |
Total Assets | 6,165 | 5,825 | 5,651 | 3,875 | 2,432 |
Accounts Payable | 798.99 | 777.27 | 636.79 | 934.95 | 340.92 |
Accrued Expenses | 34.08 | 55.28 | 57.54 | 65.7 | 57.98 |
Short-Term Debt | 60.04 | 59.32 | - | 17.64 | 20.1 |
Current Portion of Long-Term Debt | 96.57 | 77.01 | 65.9 | 66.09 | 2.84 |
Current Portion of Leases | - | 0.74 | 0.6 | 0.56 | 0.53 |
Current Income Taxes Payable | 27.23 | 3.56 | 1.15 | 38.29 | 45.65 |
Current Unearned Revenue | 19.79 | 13.87 | 19.8 | 31.01 | 29.66 |
Other Current Liabilities | 204.51 | 148.94 | 133.04 | 165.66 | 120.05 |
Total Current Liabilities | 1,241 | 1,136 | 914.83 | 1,320 | 617.73 |
Long-Term Debt | 368.34 | 230.36 | 276.12 | 341.67 | 47.22 |
Long-Term Leases | 6.42 | 7.16 | 6.9 | 8.19 | 8.23 |
Long-Term Unearned Revenue | 68.08 | 68.64 | 71.55 | 70.45 | 60.8 |
Long-Term Deferred Tax Liabilities | 21.73 | 21.62 | 21.54 | 21.31 | 20.3 |
Total Liabilities | 1,706 | 1,464 | 1,291 | 1,762 | 754.27 |
Common Stock | 400.01 | 400.01 | 400.01 | 352.75 | 352.75 |
Additional Paid-In Capital | 2,177 | 2,172 | 2,172 | 22.15 | 20.62 |
Retained Earnings | 1,925 | 1,818 | 1,786 | 1,739 | 1,304 |
Treasury Stock | -47.15 | -32.8 | - | - | - |
Comprehensive Income & Other | 4.97 | 3.37 | 1.89 | 0 | 0.46 |
Total Common Equity | 4,460 | 4,361 | 4,360 | 2,114 | 1,678 |
Minority Interest | -0.73 | 0.47 | - | - | - |
Shareholders' Equity | 4,459 | 4,361 | 4,360 | 2,114 | 1,678 |
Total Liabilities & Equity | 6,165 | 5,825 | 5,651 | 3,875 | 2,432 |
Total Debt | 531.36 | 374.59 | 349.51 | 434.14 | 78.92 |
Net Cash (Debt) | 1,070 | 1,651 | 1,831 | 51.05 | 41.51 |
Net Cash Growth | -35.20% | -9.83% | 3485.91% | 22.99% | -62.14% |
Net Cash Per Share | 2.69 | 4.14 | 4.72 | 0.14 | 0.12 |
Filing Date Shares Outstanding | 409.17 | 396.81 | 399.9 | 400.01 | 352.75 |
Total Common Shares Outstanding | 409.17 | 397.89 | 400.01 | 352.75 | 352.75 |
Working Capital | 2,056 | 1,910 | 2,287 | 345.02 | 411.91 |
Book Value Per Share | 10.90 | 10.96 | 10.90 | 5.99 | 4.76 |
Tangible Book Value | 4,281 | 4,179 | 4,177 | 1,940 | 1,484 |
Tangible Book Value Per Share | 10.46 | 10.50 | 10.44 | 5.50 | 4.21 |
Buildings | - | 833.02 | 719.62 | 395.96 | 329.31 |
Machinery | - | 1,649 | 1,470 | 782.58 | 657 |
Construction In Progress | - | 630.57 | 375.86 | 946.39 | 334.11 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.